# A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

> **NCT02778399** · PHASE2 · COMPLETED · sponsor: **ObsEva SA** · enrollment: 328 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** OBE2109

## Key facts

- **NCT ID:** NCT02778399
- **Lead sponsor:** ObsEva SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-04
- **Final completion:** 2019-07-01
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778399, "A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02778399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*